Abstract:Abstract Metastasis is the main cause of cancer-related death and prevention of metastatic relapse is, therefore, the most important goal of cancer therapy. Distant metastases harbour unique genomic characteristics not detectable in the corresponding primary tumor of the same patient and metastases located at different sites show a considerable intra-patient heterogeneity. Thus, the mere analysis of the resected primary tumor alone (current standard practise in oncology) or, if possible, even re-evaluation of tumor characteristics based on the biopsy of the most accessible metastasis may not reveal sufficient information for treatment decisions. This dilemma can be solved by a new diagnostic concept: Liquid biopsy, i.e., analysis of therapeutic targets and drug resistance-conferring gene mutations on circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) released into the peripheral blood from metastatic deposits. In addition, cell-free microRNAs in the peripheral blood of cancer patients may provide real-time insights into the biology of cancer, including the effects of therapeutic interventions. MicroRNA levels in plasma, serum, urine and other body fluids have been used to detect cancer, predict the prognosis and response to therapy. Here the current challenges and future perspectives of CTCs and circulating nucleic acids as biomarkers in clinical oncology will be discussed. Both CTCs and circulating nucleic acids are interesting complementary technologies that can be used in parallel in future trials assessing new drugs or drug combinations. We postulate that the liquid biopsy concept will contribute to a better understanding and prevention of metastatic relapse and progression in cancer patients. Citation Format: Klaus Pantel. Circulating tumor cells versus circulating tumor cell products. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr ED06-03.

Classifying circulating tumor cells to monitor cancer progression

Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential

Circulating tumor cells and DNA as liquid biopsies

Circulating tumor cells (CTCs) as a liquid biopsy material and drug target.

Position of Circulating Tumor Cells in the Clinical Routine in Prostate Cancer and Breast Cancer Patients

Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer

Breast Cancer Circulating Tumor Cells: Current Clinical Applications and Future Prospects

Circulating tumor cells: biology and clinical significance

Circulating and Disseminated Tumor Cells: Diagnostic Tools and Therapeutic Targets in Motion

Molecular Characterization of Circulating Tumor Cells-from Bench to Bedside

Tracking cancer progression: from circulating tumor cells to metastasis

Circulating Tumor Cells: A New Window For Diagnosis And Evaluation Of Cancer

Circulating tumor cells et al.: towards a comprehensive liquid biopsy approach in breast cancer

Circulating Tumor Cells in Precision Oncology: Clinical Applications in Liquid Biopsy and 3D Organoid Model

Progress of Circulating Tumor Cells in Clinical Application

Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance

Advances in circulating tumor cells for early detection, prognosis and metastasis reduction in lung cancer

Clinical significance of circulating tumor cells in breast cancer patients

Progress and Application of Circulating Tumor Cells in Non-Small Cell Lung Cancer

Clinical Applications Of Circulating Tumor Cells In Pharmacotherapy: Challenges And Perspectives

Abstract ED06-03: Circulating tumor cells versus circulating tumor cell products